The U.S. Food and Drug Administration has granted orphan drug designation to AM152, the lead drug candidate under development at San Diego’s Amira Pharmaceuticals for treating idiopathic pulmonary fibrosis, a lung disease that makes it difficult to breathe. In a statement yesterday, the company says the designation provides a seven-year period of market exclusivity and potential tax credits and regulatory advantages to the developer of a new drug therapy for diseases that affect fewer than 200,000 people in the United States. Amira says it is completing early stage tests of a compound that seems to help block the activation of a cellular receptor implicated in tissue fibrosis and related disease processes.
By posting a comment, you agree to our terms and conditions.
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences
I just read the article & hope you hurry & make it available……..I would really like a treatment that works!
Good luck.